Jasper Therapeutics (JSPR) Operating Expenses (2020 - 2025)

Jasper Therapeutics has reported Operating Expenses for 6 years, with the latest figure at $15.8 million in Q4 2025.

• On a quarterly basis, Operating Expenses fell 37.36% year-over-year to $15.8 million in Q4 2025; TTM through Dec 2025 was $83.9 million, a 10.03% increase from a year earlier, with the FY2025 full-year figure at $83.9 million, up 10.03% from the prior year.
• Operating Expenses was $15.8 million for Q4 2025 at Jasper Therapeutics, down from $19.2 million in the prior quarter.
• The five-year high for Operating Expenses was $27.1 million in Q2 2025, with the low at $6.3 million in Q1 2021.
• Average Operating Expenses over 5 years is $15.9 million, with a median of $15.5 million recorded in 2024.
• The sharpest annual moves came in 2021 and 2025: Operating Expenses soared 2634.99% in 2021, then plunged 37.36% in 2025.
• Over 5 years, Operating Expenses stood at $12.1 million in 2021, then rose by 13.78% to $13.7 million in 2022, then grew by 28.94% to $17.7 million in 2023, then soared by 42.65% to $25.3 million in 2024, then slumped by 37.36% to $15.8 million in 2025.
• The last three Operating Expenses figures came in at $15.8 million (Q4 2025), $19.2 million (Q3 2025), and $27.1 million (Q2 2025), per Business Quant data.